{"id":19476,"date":"2024-12-23T17:41:44","date_gmt":"2024-12-23T09:41:44","guid":{"rendered":"https:\/\/flcube.com\/?p=19476"},"modified":"2024-12-23T17:41:46","modified_gmt":"2024-12-23T09:41:46","slug":"gsks-jemperli-combo-shows-improved-pfs-in-phase-iii-ovarian-cancer-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19476","title":{"rendered":"GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial"},"content":{"rendered":"\n

UK-based GSK plc (NYSE: GSK<\/a>) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.<\/p>\n\n\n\n

Progression-Free Survival (PFS) and Overall Survival (OS) Outcomes<\/strong>
While the key secondary endpoint of overall survival (OS) did not achieve statistical significance, the safety and tolerability of the combination were found to be generally consistent with the known safety profiles of the individual agents. This suggests that the combination therapy may offer a viable treatment option for patients with advanced ovarian cancer without compromising safety.<\/p>\n\n\n\n

Jemperli’s Background and Development<\/strong>
Jemperli was discovered by AnaptysBio, Inc. and was licensed to TESARO, Inc. in March 2014, which was later acquired by GSK. This deal made GSK responsible for the ongoing research, development, commercialization, and manufacturing of Jemperli, as well as cobolimab (GSK4069889), a TIM-3 antagonist. Jemperli has been approved in the US for the treatment of primary advanced or recurrent endometrial cancer, either as a standalone therapy or in combination with chemotherapy.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44…<\/p>\n","protected":false},"author":1,"featured_media":19477,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,184,914,18],"class_list":["post-19476","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-gsk","tag-nyse-gsk","tag-pd-1-l1"],"yoast_head":"\nGSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19476\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial\" \/>\n<meta property=\"og:description\" content=\"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19476\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-23T09:41:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-23T09:41:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"617\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial\",\"datePublished\":\"2024-12-23T09:41:44+00:00\",\"dateModified\":\"2024-12-23T09:41:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2319.png\",\"keywords\":[\"Clinical trial results\",\"GSK\",\"NYSE: GSK\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19476#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19476\",\"name\":\"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2319.png\",\"datePublished\":\"2024-12-23T09:41:44+00:00\",\"dateModified\":\"2024-12-23T09:41:46+00:00\",\"description\":\"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19476\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2319.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2319.png\",\"width\":1080,\"height\":617,\"caption\":\"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19476#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial - Insight, China's Pharmaceutical Industry","description":"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19476","og_locale":"en_US","og_type":"article","og_title":"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial","og_description":"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.","og_url":"https:\/\/flcube.com\/?p=19476","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-23T09:41:44+00:00","article_modified_time":"2024-12-23T09:41:46+00:00","og_image":[{"width":1080,"height":617,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19476#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19476"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial","datePublished":"2024-12-23T09:41:44+00:00","dateModified":"2024-12-23T09:41:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19476"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19476#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","keywords":["Clinical trial results","GSK","NYSE: GSK","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19476#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19476","url":"https:\/\/flcube.com\/?p=19476","name":"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19476#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19476#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","datePublished":"2024-12-23T09:41:44+00:00","dateModified":"2024-12-23T09:41:46+00:00","description":"UK-based GSK plc (NYSE: GSK) has announced a positive readout from the Phase III FIRST-ENGOT-OV44 trial for Jemperli (dostarlimab), a programmed death-1 (PD-1) inhibitor, when combined with Zejula (niraparib) for the first-line treatment of advanced ovarian cancer. The trial evaluated the addition of Jemperli to the standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab, and demonstrated a significant improvement in progression-free survival (PFS), meeting the primary endpoint.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19476#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19476"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19476#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","width":1080,"height":617,"caption":"GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19476#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2319.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19476"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19476\/revisions"}],"predecessor-version":[{"id":19478,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19476\/revisions\/19478"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19477"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}